Stimulation of Antigen Presenting Cells: From Classical Adjuvants to Toll-like Receptor (TLR) Ligands

Antigen Presenting Cells: From Mechanisms to Drug Development

Volumn , Issue , 2006, Pages 221-243

  Bachmann, Martin F ^a   Oxenius, Annette ^b  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Antigen presenting cells; Composition of adjuvants; Efficient immune responses; Function of adjuvants; Ligands recognized by T and toll like receptors (TLR); Pathogen associated features; Stimulation of antigen presenting cells; Synopsis; Therapeutic potential of TLRs ligands; TLR protein family in mammals; TLR signaling

Indexed keywords

EID: 84889424022     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607021.ch8     Document Type: Chapter

References (101)

1. Kundig, T.M., A. Shahinian, K. Kawai, H.W. Mittrucker, E. Sebzda, M.F. Bachmann, T.W. Mak, and P.S. Ohashi. 1996. Duration of TCR stimulation determines costimulatory requirement of Tcells. Immunity 5: 41-52.
2. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector Tcells. Immunity 8: 89-95.
3. Storni, T., C. Ruedl, W.A. Renner, and M.F. Bachmann. 2003. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J. Immunol. 171: 795-801.
4. Carroll, M.C., and M.B. Fischer. 1997. Complement and the immune response. Curr. Opin. Immunol. 9: 64-69.
5. Matsushita, M., and T. Fujita. 2001. Ficolins and the lectin complement pathway. Immunol. Rev. 180: 78-85.
6. Bachmann, M.F., and R.M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15: 235-270.
7. Janeway, C.A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.
8. Ulevitch, R.J. 2004. Therapeutics targeting the innate immune system. Nat. Rev. Immunol. 4: 512-520.
9. Janeway, C.A., Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54 Pt 1: 1-13.
10. Beutler, B., K. Hoebe, X. Du, and R.J. Ulevitch. 2003. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74: 479-485.
11. Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2: 675-680.
12. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145.
13. Bachmann, M.F., and M.R. Dyer. 2004. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3: 81-88.
14. Chackerian, B., D.R. Lowy, and J.T. Schiller. 2001. Conjugation of a selfantigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108: 415-423.
15. Jegerlehner, A., A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, W. Renner, and M.F. Bachmann. 2002. Molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 25-30.
16. Persing, D.H., R.N. Coler, M.J. Lacy, D.A. Johnson, J.R. Baldridge, R.M. Hershberg, and S.G. Reed. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10: S32-37.
17. Bachmann, M.F., T.M. Kundig, G. Freer, Y. Li, C.Y. Kang, D.H. Bishop, H. Hengartner, and R.M. Zinkernagel. 1994. Induction of protective cytotoxic T cells with viral proteins. Eur. J. Immunol. 24: 2228-2236.
18. Lemaitre, B., E. Nicolas, L. Michaut, J.M. Reichhart, and J.A. Hoffmann. 1996. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973-983.
19. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. Shamel, S. Sovath, J. Goode, L. Alexopoulou, R.A. Flavell, and B. Beutler. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 101: 3516-3521.
20. Beutler, B., K. Hoebe, and L. Shamel. 2004. Forward genetic dissection of afferent immunity: the role of TIR adapter proteins in innate and adaptive immune responses. C.R. Biol. 327: 571-580.
21. Beutler, B., and M. Rehli. 2002. Evolution of the TIR, tolls and TLRs: functional inferences from computational biology. Curr. Top. Microbiol. Immunol. 270: 1-21.
22. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
23. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
24. Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
25. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11: 443-451.
26. Arbour, N.C., E. Lorenz, B.C. Schutte, J. Zabner, J.N. Kline, M. Jones, K. Frees, J.L. Watt, and D.A. Schwartz. 2000. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25: 187-191.
27. Wetzler, L.M. 2003. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 21(Suppl 2): S55-60.
28. Takeuchi, O., T. Kawai, P.F. Muhlradt, M. Morr, J.D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Tolllike receptor 6. Int. Immunol. 13: 933-940.
29. Girard, R., T. Pedron, S. Uematsu, V. Balloy, M. Chignard, S. Akira, and R. Chaby. 2003. Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J. Cell Sci. 116: 293-302.
30. Werts, C., R.I. Tapping, J.C. Mathison, T.H. Chuang, V. Kravchenko, I. Saint Girons, D.A. Haake, P.J. Godowski, F. Hayashi, A. Ozinsky, D.M. Underhill, C.J. Kirschning, H. Wagner, A. Aderem, P.S. Tobias, and R.J. Ulevitch. 2001. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2: 346-352.
31. Hirschfeld, M., J.J. Weis, V. Toshchakov, C.A. Salkowski, M.J. Cody, D.C. Ward, N. Qureshi, S.M. Michalek, and S.N. Vogel. 2001. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69: 1477-1482.
32. Massari, P., P. Henneke, Y. Ho, E. Latz, D.T. Golenbock, and L.M. Wetzler. 2002. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J. Immunol. 168: 1533-1537.
33. Ozinsky, A., D.M. Underhill, J.D. Fontenot, A.M. Hajjar, K.D. Smith, C.B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. U.S.A. 97: 13766-13771.
34. Wyllie, D.H., E. Kiss-Toth, A. Visintin, S.C. Smith, S. Boussouf, D.M. Segal, G.W. Duff, and S.K. Dower. 2000. Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. J. Immunol. 165: 7125-7132.
35. Akira, S. 2003. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15: 5-11.
36. Means, T.K., E. Lien, A. Yoshimura, S. Wang, D.T. Golenbock, and M.J. Fenton. 1999. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. 163: 6748-6755.
37. Henneke, P., O. Takeuchi, J.A. van Strijp, H.K. Guttormsen, J.A. Smith, A.B. Schromm, T.A. Espevik, S. Akira, V. Nizet, D.L. Kasper, and D.T. Golenbock. 2001. Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J. Immunol. 167: 7069-7076.
38. Campos, M.A., I.C. Almeida, O. Takeuchi, S. Akira, E.P. Valente, D.O. Procopio, L.R. Travassos, J.A. Smith, D.T. Golenbock, and R.T. Gazzinelli. 2001. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. Immunol. 167: 416-423.
39. Steiner, T.S., J.P. Nataro, C.E. Poteet-Smith, J.A. Smith, and R.L. Guerrant. 2000. Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J. Clin. Invest. 105: 1769-1777.
40. Eaves-Pyles, T., K. Murthy, L. Liaudet, L. Virag, G. Ross, F.G. Soriano, C. Szabo, and A.L. Salzman. 2001. Flagellin, a novel mediator of Salmonellainduced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J. Immunol. 166: 1248-1260.
41. Hayashi, F., K.D. Smith, A. Ozinsky, T.R. Hawn, E.C. Yi, D.R. Goodlett, J.K. Eng, S. Akira, D.M. Underhill, and A. Aderem. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
42. Smith, K.D., E. Andersen-Nissen, F. Hayashi, K. Strobe, M.A. Bergman, S.L. Barrett, B.T. Cookson, and A. Aderem. 2003. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4: 1247-1253.
43. Hawn, T.R., A. Verbon, K.D. Lettinga, L.P. Zhao, S.S. Li, R.J. Laws, S.J. Skerrett, B. Beutler, L. Schroeder, A. Nachman, A. Ozinsky, K.D. Smith, and A. Aderem. 2003. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J. Exp. Med. 198: 1563-1572.
44. Zhang, D., G. Zhang, M.S. Hayden, M.B. Greenblatt, C. Bussey, R.A. Flavell, and S. Ghosh. 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522-1526.
45. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, and T. Sudo. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72: 955-962.
46. Krieg, A.M., A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
47. Bogdan, C. 2000. The function of type I interferons in antimicrobial immunity. Curr. Opin. Immunol. 12: 419-424.
48. Taniguchi, T., and A. Takaoka. 2002. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14: 111-116.
49. Le Page, C., P. Genin, M.G. Baines, and J. Hiscott. 2000. Interferon activation and innate immunity. Rev. Immunogenet. 2: 374-386.
50. Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
51. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
52. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reise Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303: 1529-1531.
53. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
54. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Tolllike receptor recognizes bacterial DNA. Nature 408: 740-745.
55. Leifer, C.A., M.N. Kennedy, A. Mazzoni, C. Lee, M.J. Kruhlak, and D.M. Segal. 2004. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. 173: 1179-1183.
56. Kariko, K., H. Ni, J. Capodici, M. Lamphier, and D. Weissman. 2004. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279: 12542-12550.
57. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
58. Wesche, H., W.J. Henzel, W. Shillinglaw, S. Li, and Z. Cao. 1997. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837-847.
59. Muzio, M., J. Ni, P. Feng, and V.M. Dixit. 1997. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278: 1612-1615.
60. Yamaguchi, K., K. Shirakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, and K. Matsumoto. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011.
61. Shibuya, H., K. Yamaguchi, K. Shirakabe, A. Tonegawa, Y. Gotoh, N. Ueno, K. Irie, E. Nishida, and K. Matsumoto. 1996. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272: 1179-1182.
62. Takaesu, G., S. Kishida, A. Hiyama, K. Yamaguchi, H. Shibuya, K. Irie, J. Ninomiya-Tsuji, and K. Matsumoto. 2000. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5: 649-658.
63. Horng, T., G.M. Barton, R.A. Flavell, and R. Medzhitov. 2002. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420: 329-333.
64. Fitzgerald, K.A., E.M. Palsson-McDermott, A.G. Bowie, C.A. Jefferies, A.S. Mansell, G. Brady, E. Brint, A. Dunne, P. Gray, M.T. Harte, D. McMurray, D.E. Smith, J.E. Sims, T.A. Bird, and L.A. O'Neill. 2001. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413: 78-83.
65. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
66. Kawai, T., O. Takeuchi, T. Fujita, J. Inoue, P.F. Muhlradt, S. Sato, K. Hoshino, and S. Akira. 2001. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide- inducible genes. J. Immunol. 167: 5887-5894.
67. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17: 1087-1095.
68. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. Akira. 2002. Cutting edge: a novel Toll/ IL-1 receptor domain-containing adapter that preferentially activates the IFNbeta promoter in the Toll-like receptor signaling. J. Immunol. 169: 6668-6672.
69. Yamamoto, M., S. Sato, H. Hemmi, S. Uematsu, K. Hoshino, T. Kaisho, O. Takeuchi, K. Takeda, and S. Akira. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4: 1144-1150.
70. Fitzgerald, K.A., D.C. Rowe, B.J. Barnes, D.R. Caffrey, A. Visintin, E. Latz, B. Monks, P.M. Pitha, and D.T. Golenbock. 2003. LPS-TLR4 signaling to IRF- 3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J. Exp. Med. 198: 1043-1055.
71. Bin, L.H., L.G. Xu, and H.B. Shu. 2003. TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling. J. Biol. Chem. 278: 24526-24532.
72. Oshiumi, H., M. Sasai, K. Shida, T. Fujita, M. Matsumoto, and T. Seya. 2003. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J. Biol. Chem. 278: 49751-49762.
73. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643.
74. Royet, J., and J.M. Reichhart. 2003. Detection of peptidoglycans by NOD proteins. Trends Cell Biol. 13: 610-614.
75. Chamaillard, M., M. Hashimoto, Y. Horie, J. Masumoto, S. Qiu, L. Saab, Y. Ogura, A. Kawasaki, K. Fukase, S. Kusumoto, M.A. Valvano, S.J. Foster, T.W. Mak, G. Nunez, and N. Inohara. 2003. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4: 702-707.
76. Girardin, S.E., I.G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D.J. Philpott, and P.J. Sansonetti. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872.
77. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, S.J. Foster, A.P. Moran, J.L. Fernandez-Luna, and G. Nunez. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278: 5509-5512.
78. Inohara, N., and G. Nunez. 2003. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3: 371-382.
79. Martinon, F., and J. Tschopp. 2004. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574.
80. Girardin, S.E., J.P. Hugot, and P.J. Sansonetti. 2003. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24: 652-658.
81. Samuel, C.E. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14: 778-809, table of contents.
82. Saunders, L.R., and G.N. Barber. 2003. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 17: 961-983.
83. Herre, J., A.S. Marshall, E. Caron, A.D. Edwards, D.L. Williams, E. Schweighoffer, V. Tybulewicz, E.S.C. Reis, S. Gordon, and G.D. Brown. 2004. Dectin-1 utilizes novel mechanisms for yeast phagocytosis in macrophages. Blood 104: 4038-4045.
84. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R.L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169: 10-14.
85. Aliprantis, A.O., R.B. Yang, M.R. Mark, S. Suggett, B. Devaux, J.D. Radolf, G.R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285: 736-739.
86. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C.J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274: 17406-17409.
87. Opitz, B., N.W. Schroder, I. Spreitzer, K.S. Michelsen, C.J. Kirschning, W. Hallatschek, U. Zahringer, T. Hartung, U.B. Gobel, and R.R. Schumann. 2001. Tolllike receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J. Biol. Chem. 276: 22041-22047.
88. Underhill, D.M., A. Ozinsky, A.M. Hajjar, A. Stevens, C.B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401: 811-815.
89. Kurt-Jones, E.A., L. Popova, L. Kwinn, L.M. Haynes, L.P. Jones, R.A. Tripp, E.E. Walsh, M.W. Freeman, D.T. Golenbock, L.J. Anderson, and R.W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1: 398-401.
90. Rassa, J.C., J.L. Meyers, Y. Zhang, R. Kudaravalli, and S.R. Ross. 2002. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc. Natl. Acad. Sci. U.S.A. 99: 2281-2286.
91. Yamamoto, S., T. Yamamoto, S. Shimada, E. Kuramoto, O. Yano, T. Kataoka, and T. Tokunaga. 1992. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 36: 983-997.
92. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186: 1623-1629.
93. Roman, M., E. Martin-Orozco, J.S. Goodman, M.D. Nguyen, Y. Sato, A. Ronaghy, R.S. Kornbluth, D.D. Richman, D.A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3: 849-854.
94. Krieg, A.M. 2003. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9: 831-835.
95. Meraldi, V., R. Audran, J.F. Romero, V. Brossard, J. Bauer, J.A. Lopez, and G. Corradin. 2003. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 21: 2485-2491.
96. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200.
97. Brandenburg, K., B. Lindner, A. Schromm, M.H. Koch, J. Bauer, A. Merkli, C. Zbaeren, J.G. Davies, and U. Seydel. 2000. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur. J. Biochem. 267: 3370-3377.
98. O'Hagan, D.T., and N.M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2: 727-735.
99. Gursel, I., M. Gursel, K.J. Ishii, and D.M. Klinman. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167: 3324-3328.
100. Storni, T., C. Ruedl, K. Schwarz, R.A. Schwendener, W.A. Renner, and M.F. Bachmann. 2004. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic Tcell responses in the absence of systemic side effects. J. Immunol. 172: 1777-1785.
101. Schwarz, K., T. Storni, V. Manolova, A. Didierlaurent, J.C. Sirard, P. Rothlisberger, and M.F. Bachmann. 2003. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33: 1465-1470.